The assessment and impact of sarcopenia in lung cancer: a systematic literature review by Collins, Jemima et al.
The assessment and impact
of sarcopenia in lung cancer:
a systematic literature review
Jemima Collins,1 Simon Noble,2 John Chester,3 Bernadette Coles,4 Anthony Byrne5
To cite: Collins J, Noble S,
Chester J, et al. The
assessment and impact
of sarcopenia in lung cancer:
a systematic literature review.
BMJ Open 2014;4:e003697.
doi:10.1136/bmjopen-2013-
003697
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-003697).
Received 1 August 2013
Revised 20 November 2013
Accepted 2 December 2013
1Cardiff University, Cardiff,
UK
2Department of Palliative
Medicine, Cardiff University,
Cardiff, South Wales, UK
3Department of Medical
Oncology, Cardiff University,
Cardiff, South Wales, UK
4Cancer Research Wales
Library, Velindre NHS Trust,
Cardiff, South Wales, UK
5Marie Curie Palliative Care
Research Centre, Cardiff
University, Cardiff,
South Wales, UK
Correspondence to
Dr Jemima Collins;
jemimacollins@doctors.net.uk
ABSTRACT
Objectives: There is growing awareness of the
relationship between sarcopenia (loss of muscle mass
and function), and outcomes in cancer, making it a
potential target for future therapies. In order to inform
future research and practice, we undertook a
systematic review of factors associated with loss of
muscle mass, and the relationship between muscle
function and muscle mass in lung cancer, a common
condition associated with poor outcomes.
Design: We conducted a computerised systematic
literature search on five databases. Studies were
included if they explored muscle mass as an outcome
measure in patients with lung cancer, and were
published in English.
Setting: Secondary care.
Participants: Patients with lung cancer.
Primary outcome: Factors associated with loss of
muscle mass and muscle function, or sarcopenia, and
the clinical impact thereof in patients with lung cancer.
Results: We reviewed 5726 citations, and 35 articles
were selected for analysis. Sarcopenia, as defined by
reduced muscle mass alone, was found to be very
prevalent in patients with lung cancer, regardless of
body mass index, and where present was associated
with poorer functional status and overall survival. There
were diverse studies exploring molecular and metabolic
factors in the development of loss of muscle mass;
however, the precise mechanisms that contribute to
sarcopenia and cachexia remain uncertain. The effect
of nutritional supplements and ATP infusions on
muscle mass showed conflicting results. There are very
limited data on the correlation between degree of
sarcopenia and muscle function, which has a non-
linear relationship in older non-cancer populations.
Conclusions: Loss of muscle mass is a significant
contributor to morbidity in patients with lung cancer.
Loss of muscle mass and function may predate
clinically overt cachexia, underlining the importance of
evaluating sarcopenia, rather than weight loss alone.
Understanding this relationship and its associated
factors will provide opportunities for focused
intervention to improve clinical outcomes.
INTRODUCTION
Over the last decade, there has been increas-
ing recognition of the clinical importance of
sarcopenia as part of the cancer cachexia
syndrome, and its impact has been evaluated
in a wide range of malignancies including
lung, breast, upper gastrointestinal, hepato-
cellular and colorectal cancers.1–5 The term
sarcopenia is derived from the Greek
meaning ‘poverty of ﬂesh’ and is charac-
terised by a triad of progressive loss of skel-
etal muscle mass, muscle strength and
physical performance.6 It was originally
described in the elderly non-cancer popula-
tion, and is often now deﬁned as a geriatric
syndrome associated with functional impair-
ment, increased risk of falls, fractures and
reduced survival.7–9 Sarcopenia becomes
more prevalent with increase in age—of
1421 healthy adults aged 45 years or over, the
overall prevalence was 15%, rising to 64%
over the age of 85.10 This loss of muscle mass
is usually gradual and not necessarily asso-
ciated with signiﬁcant or sudden weight loss.
The detrimental effects of sarcopenia can
also be seen in younger patients in association
with muscle disuse, malnutrition or inﬂamma-
tory conditions, particularly cancer. Interest in
sarcopenia as a poor prognostic indicator in
cancer is rising; in various populations with
cancer sarcopenia is associated with poorer
performance status (PS),1 reduced overall sur-
vival11 12 and increased risk of chemotherapy
toxicities.2 4 This interest is reﬂected in a
recent international consensus on the deﬁn-
ition of cancer cachexia, which established
sarcopenia as a key diagnostic criterion.13
Strengths and limitations of this study
▪ Timely systematic review considering the
increasingly recognised phenomenon of sarcope-
nia as it relates to cachexia.
▪ Evaluation of sarcopenia in lung cancer, as an
example of a common cancer associated with poor
outcomes and a significant prognostic impact.
▪ Limited to publications in English only.
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The hallmark of sarcopenia is low muscle mass, more
speciﬁcally an appendicular skeletal muscle mass index of
more than 2 SDs below the sex-speciﬁc mean of healthy
adults (ie, 5.45 kg/m2 for women and 7.26 kg/m2 for
men).8 However, central to the concept of sarcopenia is
the recognition that overall neuromuscular function,
rather than muscle mass alone, is essential for mainten-
ance of independence. Therefore, when deﬁning sarcope-
nia, it is vital to assess muscle strength, or physical
performance, in addition to muscle mass, as the relation-
ship between muscle mass and strength is non-linear.14 15
While many different techniques have been used to
measure muscle mass and strength, few have been incor-
porated into routine assessment of the cancer popula-
tion. The current gold standards are CT, MRI and
dual-energy X-ray absorptiometry (DEXA) scans. CT and
MRI allow precise differentiation between fat and other
soft tissue including muscle and are therefore investiga-
tions of choice. CT focuses on a speciﬁc area of the
body—for example, muscle cross-sectional area at the
third lumbar vertebra—which can be related to whole
body muscle mass. It is the current gold standard in
body composition research and has the advantage that
many patients will have CT scans as part of their diagnos-
tic and treatment assessments. However, DEXA involves
less radiation exposure compared with CT and accur-
ately and precisely differentiates between lean and fat
body compartments.16 More indirect techniques for
measuring muscle mass include bioelectrical impedance
analysis which is non-invasive but less accurate compared
with DEXA. It includes a measure of organ mass other
than skeletal muscle, but is easily performed in clinical
settings.17 Measurements of mid-upper arm circumfer-
ence and arm muscle area using skinfold thickness
methods have also been used,18 although these assess-
ments are less accurate and there exists considerable
interobserver variability. Measurements of muscle
strength in the literature have mainly centred around
handgrip strength (HGS) and quadriceps strength,
although in non-cancer elderly patients, functional
assessments such as the Short Physical Performance
Battery and sit-to-stand tests19 20 have been shown to cor-
relate with adverse outcomes.
From the literature it is clear that there is marked
diversity in current clinical practice in assessing the
degree of muscle loss in patients with cancer and in
quantifying its functional implications. If the loss of
muscle mass and strength have signiﬁcant clinical impli-
cations for patients with cancer, then standardised, vali-
dated diagnostic thresholds are clearly needed.
Furthermore, while the effects of sarcopenia have been
extensively studied in the elderly patients, factors asso-
ciated with loss of muscle mass and strength in cancer
remain unclear. As the pathophysiological mechanisms
responsible for loss of muscle mass in cancer differ, at
least in part, from those in sarcopenia of ageing, it is
necessary to evaluate cancer-speciﬁc causative factors
and clinical implications.
We therefore undertook a systematic literature review
to further understand the relationship between muscle
function and muscle mass and its implications for
research and clinical practice within the context of
cancer. We limited the review to focus on lung cancer as
an example of a common cancer, associated with poor
outcomes, in which sarcopenia has been shown to have
a signiﬁcant prognostic impact. Lung cancer has a
worldwide incidence rate of 1.61 million cases per
year,21 and frequently presents in the advanced stages.
Despite advances in anticancer therapies, survival bene-
ﬁts in patients with lung cancer over the past 30 years
have been relatively small compared with those seen in
breast, colorectal and prostate cancers.22 While reasons
for this are complex, many patients with lung cancer are
ineligible for radical treatment at presentation due to
poor PS or comorbidity, while others fail to receive their
intended treatment plan because of functional
decline.23 24 Non-small cell lung cancer (NSCLC) has a
particularly strong association with loss of muscle mass—
of 441 patients consecutively referred to a regional
oncology service, 47% were found to be sarcopenic.25
This prevalence can be compared with 16% of a cohort
of 471 survivors with breast cancer26 and 39% in a
cohort of 234 patients with preoperative colorectal
cancer.5 We conducted this systematic review with this in
mind.
METHODS
Search strings and data sources
We not only executed a broad literature search, includ-
ing various terminologies used to describe loss of muscle
mass, but also speciﬁcally used ‘sarcopenia’ as a multi-
purpose ﬁeld search term. Recognising that changes in
muscle mass may impact on muscle strength and phys-
ical function, we included these terms in our search. We
united two search strings: loss of muscle mass (and its
implications) and lung cancer (see table 1). The search
was limited to English language and humans, with a
publication date from 1946 to October 2013. We used
the same search strings to develop strategies in the fol-
lowing ﬁve databases in order to ensure maximal cover-
age: MEDLINE, MEDLINE In-Process, EMBASE, AMED
and the Cochrane library.
Article retrieval
Citations were independently screened by two research-
ers ( JCo and SN) and included for initial analysis if they
described muscle mass measurements or body compos-
ition in patients with lung cancer. Both prospective and
retrospective original articles were included, but confer-
ence abstracts, citations without abstracts, case reports,
review articles and opinion pieces were excluded. All
studies that had a cohort of patients with lung cancer
were included, even if there were patient groups with
other cancer types analysed. Retrieved articles were
searched for additional relevant references.
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Inclusion criteria and data extraction
The selected articles were reviewed in full by two inde-
pendent researchers ( JCo and SN) for consideration of
inclusion in the review. Where discordance in selection
was observed, the article in question was discussed until
consensus was reached. As there were many articles
describing muscle mass as part of routine anthropom-
etry or body composition assessments, without directly
exploring it, we only included articles in which muscle
mass was explored as an outcome measure. Data includ-
ing patient characteristics and numbers, histological
subtype and TNM (tumour, node, metastasis) stage were
collated and tabulated (tables 2 and 3). We also noted
units of muscle mass measurements, and techniques
used to measure these.
RESULTS
Using our broad search terms in ﬁve databases, we found
an initial 5726 citations, from which we identiﬁed 64
potentially relevant articles. Three further potential arti-
cles27–29 were identiﬁed from the references of these arti-
cles. From these, we excluded 11 abstracts with no
published articles, 2 further abstracts that did not
mention muscle mass,30 31 and a systematic review of
cancer cachexia.32 Of the 53 ﬁnal articles, we excluded a
further 13 articles which mentioned muscle mass in base-
line anthropometry details but did not use it as an
outcome measure,33–45 4 articles which described weight
loss rather than loss of muscle mass,46–49 and 1 article
describing the same results obtained from the same
patient population as another article,50 with slightly dif-
ferent secondary endpoints.51 During the process of data
extraction, a number of recurring themes became appar-
ent. We have presented these under two main headings
—factors associated with loss of muscle mass, and degree
of loss of muscle mass and physical functioning.
A number of studies explored multiple variables asso-
ciated with loss of muscle mass, and are therefore men-
tioned under more than one heading.
For the ﬁnal analysis, 4 randomised controlled studies,
17 cross-sectional studies and 14 longitudinal studies
met the established criteria: 35 articles in total. Muscle
mass data were reported variously as fat-free mass
(FFM), body cell mass, lean body mass, appendicular
skeletal muscle mass, smooth muscle area at the levels of
lumbar vertebra L3 and thoracic vertebra T4, mid-upper
arm circumference and arm muscle area. Notably, most
studies described muscle mass in more than one way.
Muscle function was described as HGS and/or quadri-
ceps strength,17 27 52–54 intensity of physical activity,55
patient-reported physical functioning28 and muscle
strength and physical performance.56
As the studies in our review expressed muscle mass in
different ways, we have used the term FFM or loss of
muscle mass in the body of our article in order to allow
direct comparison. In addition, where the studies in this
review deﬁned a patient group as having sarcopenia,
they did so based on loss of muscle mass alone, without
evaluation of muscle strength or performance. This
needs to be borne in mind wherever the term sarcope-
nia is used throughout this review.
Factors associated with loss of muscle mass
In this review, many studies found that those with cach-
exia and/or weight loss also had coexistent loss of
muscle mass.25 28 58 67 68 71 74 Despite this, none of the
studies prospectively evaluated the impact of loss of
muscle mass on cancer outcomes, speciﬁcally relating to
treatment. Three studies explored the loss of muscle
mass comparing men and women, ﬁnding that a signiﬁ-
cantly greater percentage of men were affected,25 64 and
that they exhibited a decreasing trend in FFM after
chemotherapy compared with baseline, whereas women
did not.29 Reﬂecting the process of loss of muscle mass in
the different stages of cancer, a study of 60 patients with
preoperative NSCLC with stage I and II disease showed
no difference in FFM compared with controls,27 whereas
in a cohort of 352 patients with advanced cancer, 84% of
those with cachexia had a reduced FFM.74
The pathophysiology of loss of muscle mass in patients
with lung cancer is complex, as illustrated in the diver-
sity of articles exploring this. Low FFM has been asso-
ciated with low albumin and high acute phase protein
concentrations,57 58 71 reﬂecting the inﬂammatory path-
ways involved. Abnormal protein metabolism is impli-
cated in the development of sarcopenia; however, in this
review, neither anabolic58 nor proteolytic pathways59 55
had any consistent effect on loss of muscle mass. The
exception to this was the lysosomal protease cathepsin-B,
which was signiﬁcantly increased in depleted FFM
patients.59 The pathophysiology may also differ depend-
ing on disease stage and cachexia phase. There is some
evidence, for example, that in patients with precachectic
NSCLC, despite weight loss, the ubiquitin–proteasome
Table 1 Search strings and terms
Search strings Search terms
Loss of muscle
mass
Sarcopenia OR
Muscle atrophy OR
Muscle weakness OR
Muscle mass OR
Muscle wasting OR
Muscle loss OR
Weight loss OR
Muscle strength OR
Physical fitness OR
Physical exertion OR
Activities of daily living OR
Cachexia
AND
Lung cancer Lung (neoplasm OR malignancy OR
tumour)
Pleural (neoplasm OR malignancy OR
tumour)
Collins J, Noble S, Chester J, et al. BMJ Open 2014;4:e003697. doi:10.1136/bmjopen-2013-003697 3
Open Access
 group.bmj.com on April 29, 2014 - Published by bmjopen.bmj.comDownloaded from 
Table 2 Loss of muscle mass as outcome measures and factors associated with it
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
McMillan (2001)57 40 (40/0) NSCLC n=11,
upper GI n=22,
colon n=7
All locally
advanced or
metastatic
BCM Total body
potassium
Cross
sectional
Nil The inter-relationship
between albumin, body
cell mass and the
systemic inflammatory
response
Albumin concentrations
correlated with BCM
(r=0.686, p<0.001) and
negatively correlated
with CRP (r=−0.545,
p<0.001)
Crown (2002)58 30 (NR/
NR)
NSCLC in all
Inoperable, stage
NR
FFM, MUAC BIA, upper
arm
measurements
Case-control,
longitudinal
over 2 years
n=30 HV ILGF system and
cancer cachexia
More LC than HV had
MAMC in the lowest
quartile (p<0.05) at
baseline,
Male LC patients had
lower FFM than male
HV (p<0.05) at
baseline,
No significant
longitudinal trend
observed in IGFBP-3
and IL-6 and nutritional
status, p=NS
Jagoe (2002)59 36 (27/9) Mix of NSCLC
and SCLC
Stage 1–21
Stage 2–6
Stage 3–6
Stage 4–2
FFMi BIA, Four
skinfold
method, %
BFMAMA
Cross
sectional
n=10
patients
referred for
thoracotomy
for
non-malignant
conditions
Ubiquitin-proteasome
and lysosomal
proteolytic pathway
gene expression in LC
and association with
LMM
Cathepsin B
expression in LC
inversely related to
FFMi, p=0.003;
Cathepsin-B
expression increased
in ‘depleted FFMi
cancer patients’ vs
controls p=0.003;
No relationship
between cathepsin B
expression and
%BFMAMA, p=NS
Wieland (2007)60 286 (NR/
NR)
NSCLC n=181,
stage IIIB or IV
SMA at T4 CT at T4 Longitudinal n=7 HV Establish prevalence of
PIF in patients with
cancer, and its
association with
muscle loss
In patients with
NSCLC:
PIF unrelated to
survival and muscle
loss, p=NS;
PIF positive patients
rate of loss of muscle
mass per 100 days
Continued
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
−3.4±2.1% vs PIF
negative patients
−2.4±1.7%, p=NS
Martinez-Hernandez
(2012)61
21 (19/2) LC n=13, GI
cancer n=6,
Other cancer n=2
Stage according
to tumour group
NR
FFM BIA Longitudinal n=8 HV The role of IL-15) in
patients with cachectic
cancer
At weeks 4 and 8,
patients with cancer
lost FFM in tandem
with decreasing IL-15
levels, r=0.514 and
r=0.535, both p<0.05
Op den Kamp
(2012)55
16 (15/1) NSCLC in all
Stage I–II—11
Stage IIIA—2
Stage IIIB—3
FFMi DEXA Cross
sectional
n=10 HV Skeletal muscle NF-κB
and ubiquitin
proteasome system
activity in precachexia
FFMi no significant
difference in
precachectic cancer vs
controls, p=NS;
NF-κB, UPS E3-ligase
and 26S proteasome
activity not raised in
patients with
precachectic cancer,
all p=NS
Vigano (2009)52 N=172
(101/71)
NSCLC n=64, All
stage III and IV.
Metastatic GI
cancer n=108
LBM, ALM DEXA (n=64) Cross
sectional
Nil ACE gene
polymorphism
(insertion2-II, insertion/
deletion-ID,
deletion2-DD) on
nutritional status
Trend (p=0.07)
towards lower LBM in
ID compared to
II groups
Op den Kamp
(2013)62
26 (17/9) NSCLC
Stage IIIB—10
Stage IV—16
FFMi, AMMi DEXA Cross
sectional
n=10 HV Expression of
signalling molecules in
protein metabolism in
LC cachexia
AMMi 20% lower in
cachectic group
compared with
controls, p<0.05;
Akt concentration
increased in cachectic
group (p<0.05), but no
downstream signal
phosphorylation, that
is, impaired anabolic
activity
Harvie (2003)29 50 (32/18) NSCLC in all,
stage III and IV
FFM Four skinfold
method
Longitudinal Nil Exploration of
gender-specific
differences in body
composition and REE
Trend for FFM to
decrease (p=0.063)
and FFM decreased
(p<0.05) in men after
Continued
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
prechemotherapy and
postchemotherapy
chemotherapy. No
significant difference in
FFM or REE in women
Harvie (2005)63 43 (28/15) NSCLC in all,
stage III and IV.
Alongside this
metastatic breast
and melanoma
patients
evaluated
separately
FFM Four skinfold
method
Longitudinal Nil Relationship between
energy intake, REE
and acute phase
response vs changes
in body composition
over course of
chemotherapy
No significant change
in FFM over the course
of chemotherapy, and
no significant
relationship with
energy intake, REE or
CRP (all p=NS)
Bovio (2008)64 144 (92/
52)
LC n=46, colon
n=22, HCC n=11,
other n=65
Stage NR
AMA Upper arm
measurements
Cross
sectional
Nil Evaluation of nutritional
status in patients with
advanced cancer
63% men vs 19%
women had AMA<5th
centile (p<0.01)
Baracos (2010)25 441 (229/
212)
NSCLC in all
Stage III—206
Stage IV—235
SMA at L3 CT of L3 Cross
sectional
Nil The use of CT images
in evaluating body
composition in NSCLC
61.1% men in cohort
were sarcopenic,
31.3% of women
sarcopenic, p<0.001
Martin (2013)65 1473 (828/
645)
Colorectal cancer
n=773, LC
n=440, other GI
cancer n=260
Stage according
to cancer NR
SMA at L3, SMAi CT of L3 Longitudinal Nil Prognostic significance
of weight loss, muscle
mass index and
muscle attenuation
Concordance model
using variables of BMI,
weight loss, MI and
MA found a
concordance statistic
(predictive accuracy of
survival) of 0.92
Regardless of BMI, pts
with weight loss, low
MI and MA reduced
survival (8.4 months),
compared to those with
none of these features
(28.4 months), p<0.001
Prado (2013)66 368 (216/
152)
NSCLC n=242
GI tract cancer
n=126
SMA at L3 CT of L3 Longitudinal Nil Clinical course of
skeletal muscle
wasting in advanced
cancer
Being <90 days from
death increases risk of
muscle loss, OR 2.67,
p=0.002; and
decreases chance of
Continued
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
muscle gain, OR=0.37,
p=0.002
Hansell (1986)67 98 (63/35) Colorectal cancer
n=55, gastric
cancer n=24, LC
n=12, other
cancer n=7
Stage NR
LBM, MUAC Tritiated
saline, upper
arm
measurements
Cross
sectional
n=38
non-malignant
illnesses
REE in weight-losing
patients with cancer
WLC=weight-losing
patients with cancer,
WSC=weight-stable
patients with cancer,
WSC on=weight-stable
controls
WLC compared to
WSC had lower LBM
(p<0.005);
WLC compared to
WSC and WSC on
lower MAMC
(p<0.0005);
WLC had increased
REE/kg bodyweight
compared with both
WS groups (p<0.005);
No significant
difference when REE
is expressed in terms
of kg LBM;
WLC had positive
relationship with REE,
r=0.83, p<0.001
Fredrix (1990)68 39 (GCR
13/9, LC
16/1)
LC n=17
GCR—n=22
Stage NR
FFM BIA Cross
sectional
n=40 healthy REE and weight loss FFM: LC 50.4±8.9,
Controls 51.1±9.6,
p=NS;
REE/FFM: LC
33.5±5.4, Controls
29.6±2.9, p<0.01
Staal-van den Brekel
(1997)69
12 (10/2) All SCLC FFM BIA Longitudinal Nil Assess REE and
systemic inflammation
prechemotherapy and
postchemotherapy
No change in FFM
postchemotherapy
(p=NS). Absolute REE
and REE adjusted for
FFM decreased
postchemotherapy
(p<0.005)
Simons (1997)70 21 (21/0) NSCLC n=19
Stage I—3
Stage III—5
Stage IV—11
FFM, FFMi DEXA Cross
sectional
Nil Relationship between
DL expression, body
composition and REE
DL vs non-DL no
significant difference
between groups with
regards FFM, FFMi,
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
SCLC n=2
Limited stage—2
and REE/FFM, all
p=NS
Simons (1999)71 20 (20/0) NSCLC n=18
I–II—2
III—5
IV—11
SCLC n=2
BCM, BCMi DEXA Cross
sectional
Nil Relationship between
weight loss, low BCM
and systemic
inflammation
BCM lower in group
with weight loss ≥10%
compared to group
with weight loss <10%,
p=NS;
Low BCMi associated
with high REE/BCM,
r=−0.54, p=0.03;
BCMi positively
correlated with
Karnofsky PS, p=0.02
Scott (2001)72 12 (12/0) NSCLC in all,
locally advanced
BCM Total body
potassium
Longitudinal n=7, healthy
participants
Inter-relationship
between systemic
inflammation and REE
preonset and postonset
of weight loss
Cancer group had
lower REE (p<0.05)
and BCM (p<0.001).
Cancer group REE
adjusted for BCM
correlated with CRP
concentrations
(r=0.753, p<0.01)
Jatoi (2001)73 18 (10/8) NSCLC in all
Stage IA—6
Stage IB—3
Stage IIB—3
Stage IIIA—4
Stage IIIB—2
FFM, BCM, LBM DEXA,
Potassium-40,
tritium dilution
Cross
sectional
n=18, HV REE in non-metastatic
NSCLC
REE in cancer vs
controls significantly
raised when adjusted
for LBM, p=0.001;
and also when
adjusted for BCM,
p=0.032
Jagoe (2001)27 60 (43/17) LC in all FFM, MAMC,
BFMAMA
BIA, four
skinfold
thickness,
upper arm
measurements
Cross
sectional
n=22, mild
COPD
Nutritional status of
patients undergoing LC
operations
No difference in FFMi
and BFMAMA
comparing LC and
controls, all p=NS
Sarhill (2003)74 n=352 but
LC only
18% of
cohort ()
NR MUAC, AMA BIA (n=329) Cross
sectional
Nil Prospective evaluation
of nutritional status in
advanced cancer
Cachexia group vs
non-cachexia group,
reduced AMA in 84%
vs 69%, p=0.037
Prado (2008)1 n=250,
with LC 60
(24%) of
TNM for cohort
Stage I—24
Stage II—56
SMA and SMAi
at L3
CT of L3 Cross
sectional
Nil Prevalence of
sarcopaenic obesity
and chemotherapy
SMA in OS
128.1±29.1, ONonS
160±38.1, p<0.0001
Continued
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
cohort
(136/114)
Stage III—74
Stage IV—96
toxicity in this cohort
OS=obese sarcopaenic
ONonS=obese
non-sarcopaenic
SMAi in OS 43.3±6.3,
ONonS 56.4±9.9;
Median survival assoc
with sarcopenia log
rank, p<0.0001, OS
11.3 months and
ONonS 21.6 months,
p<0.0001
Kilgour (2010)53 n=84, with
LC 16
(19%) of
cohort (48/
36)
Metastatic 57%,
locally advanced
43%, stage NR
SMMI, ALM DEXA Cross
sectional
Nil Relationship of fatigue
to muscle mass and
strength
Brief fatigue index
associated with SMMI
(95% CI −8.4 to −1.3)
p<0.01, and
sarcopenia, p<0.01
Peddle-McIntyre
(2012)56
17 (7,10) NSCLC n=16
Stage I–II—11
Stage III—5
Limited stage
SCLC n=1
LBM, ALM DEXA Longitudinal,
duration
10 weeks
Nil Resistance exercise
training efficacy and
feasibility in LC
survivors
LBM and ALM no
change from baseline
to post training, all
p=NS
Bauer (2005)75 n=7, with
NSCLC 2
(28.6%) of
cohort
Adenocarcinoma
pancreas n=5,
NSCLC n=2
Stage NR
LBM Deuterium
dilution
Longitudinal,
duration
10 weeks
Nil Effect of nutrition
counselling and EPA
supplements on body
composition
Change in LBM post
intervention, p=NS
Fearon (2006)28 518 (355/
163)
LC n=231
Upper GI cancer
n=198
Other GI cancer
n=89
Stage NR
LBM BIA RCT (double
blind, placebo
controlled,
randomised)
Nil Effect of 2 g and 4 g
doses of EPA diester
vs placebo in the
process of cachexia
Group given 2 g EPA
gained mean 0.9 kg
LBM and group given
4 g EPA lost mean
0.1 kg LBM compared
to placebo (p=NS)
Tozer (2008)54 66 (49/17);
only 35
completed
study
All LC
Stage NR
BCM NR RCT (double
blind, placebo
controlled,
randomised)
Nil Effect of cysteine-rich
protein supplement on
body weight and body
cell mass
Cysteine group +11.55
±18.05% vs control
group
−5.47±34.63% after
treatment (p=0.01),
and compared to
baseline (p=0.02)
Murphy (2010)76 41 (19/22) NSCLC in all
Stage I—2
Stage II—2
SMA at L3 CT of L3 Longitudinal,
cohort study
Nil Relationship between
muscle mass, rate of
Sarcopenia at baseline
in 63% men and 59%
women;
Continued
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
Stage III—13
Stage IV—24
over
2.5 months
muscle mass change,
and plasma fatty acids
Patients with
sarcopenia had lower
plasma EPA
(p=0.001), lower
plasma DHA
(p=0.003), and lower
n-3 fatty acids
(p=0.002) compared to
non-sarcopenic
patients
Murphy (2011)77 40 (21/19) NSCLC in all
Stage III—13
Stage IV—27
SMA at L3 CT of L3 Longitudinal,
duration
6 weeks
Open label
study
Nil controls;
cohort divided
into those
receiving FO
n=17 and SC
n=24
Effect of FO on body
composition
Sarcopenic at baseline
FO 46%, SC 46%;
Muscle loss rate per
100 days, FO 0.1
±1.6%,
SC −6.8±2.6%,
p<0.05;
Positive relationship
between plasma EPA
concentration and rate
of muscle gain,
r2=0.55, p=0.01
Winter (2012)78 10 (10/0) NSCLC in all
Stage IIIA—2
Stage IIIB—3
Stage IV—5
LBM, AMMi DEXA Longitudinal n=10
healthy men
Effect on protein
anabolism in response
to
hyperaminoacidaemia,
in cachexic
insulin-resistant
patients
Mean AMMi cancer
group defined as
sarcopenic, p=NS;
Hyperaminoacidaemia
stimulates a normal
anabolic protein
response, p<0.05
Agteresch (2002)50 58 (38/20) NSCLC in all
including controls
(RCT)
All Stage IIIB or
IV, breakdown
NR
FFM, MUAC,
BCM
Four skinfold
thickness,
deuterium
dilution
Longitudinal,
duration
28 weeks
RCT
Randomised
to ATP group
n=28, to
control group
n=30, all
NSCLC
Effect of ATP on body
composition
FFM −0.5 kg in
controls, but +0.1 kg in
ATP group, between
group difference
p=0.02
MUAC −1.8% in
controls, but +1.1% in
ATP group, between
Continued
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Table 2 Continued
First author (year)
Patients Study
Comparison Resultn (M/F) Tumour, stage
Muscle mass
measurement(s)
Method of
measurement Design Controls
group difference
p=0.02
BCM −0.6% per
4 weeks in controls,
but −0.1% in ATP
group, between group
diff p=0.054
Beijer (2009)79 n=100,
with LC
n=44
n=57
completed
8-week
study
period
LC in 44% (most
frequent), colon
cancer 13%,
various other
cancers 43%
Stage NR
‘preterminal’
MUAC Upper arm
measurements
Longitudinal,
duration
8 weeks
RCT
Baseline: ATP
n=51, SC
n=49;
Completed
study:
ATP n=29, SC
n=28
Effect of ATP on
nutritional status and
survival
Post ATP loss of
MUAC
−2.24 mm, SC group
−1.52 mm, p=NS
Short term 0–8 weeks
survival benefit with
ATP (HR 0.17,
p=0.023), and long
term 0–6 months
survival benefit (HR
0.35, p=0.025)
ALM, appendicular lean mass; AMA, arm muscle area; AMMi, appendicular muscle mass index; BCM, body cell mass; BCMi, BCM index; BFMAMA, bone free mid arm muscle area; BIA,
bioelectrical impedance analysis; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; CT of L3, CT of the third lumbar space; DEXA, dual-energy
X-ray absorptiometry; DL, detectable leptin; EPA, eicosapentaenoic acid; F, female; FFM, fat-free mass; FFMi, FFM index; FO, fish oil; GCR, gastric and colorectal cancer; GI, gastrointestinal;
HV, healthy volunteers; IL-15, interleukin 15; ILGF, insulin-like growth factor; LBM, lean body mass; LC, lung cancer; M, male; MI, muscle index; MUAC, mid-upper arm circumference; MA,
muscle area; NR, not recorded; NS, non-significant; NSCLC, non-small cell lung cancer; PS, performance status; RCT, randomised controlled trial; REE, resting energy expenditure; SCLC,
small cell lung cancer; SMA at L3 or T4, skeletal muscle area at the level of the lumbar vertebra L3 or thoracic vertebra T4; SMAi, skeletal muscle area index; SMMI, skeletal muscle mass
index; TNM, tumour, node, metastasis; HCC, hepatocellular carcinoma; MAMC, mid-arm circumference; PIF, proteolysis inducing factor.
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Table 3 Degree of loss of muscle mass and physical functioning
First author (year)
Patients Study
Comparison ResultN (M/F) Tumour, stage
Muscle function
and muscle mass
measurements
Method of
measurement Design Controls
Jagoe (2001)27 60 (43/17) LC in all Grip strength
Z-score
FFM, MAMC,
BFMAMA
HDA dynamometer
BIA, four
skinfold-thickness,
upper arm
measurements
Cross
sectional
n=22, mild
COPD
Nutritional status
of patients
undergoing lung
cancer
operations
Grip strength in
absolute terms or
Z-score no
difference LC vs
controls, p=NS
No difference in
FFMi and BFMAMA
comparing LC and
controls, all p=NS
Fearon (2006)28 518
(355/163)
LC n=231
Upper GI cancer
n=198
Other GI cancer
n=89
Stage NR
LBM BIA RCT (double
blind, placebo
controlled,
randomised)
Nil Effect of 2 g and
4 g doses of EPA
diester vs
placebo in the
process of
cachexia
Patient-reported
physical functioning
increased by 7% in
group receiving 2 g
EPA compared with
controls (p=0.04)
Tozer (2008)54 66 (49/17);
only 35
completed
study
All LC
Stage NR
BCM NR RCT (double
blind, placebo
controlled,
randomised)
Nil Effect of
cysteine-rich
protein
supplement on
body weight and
body cell mass
Handgrip force
improved by +12.41
±16.52% in cysteine
group compared to
baseline (p=0.019)
Trutschnigg (2008)17 81 (NR/
NR)
74
completed
muscle
function
tests
(48/26)
Patients with
advanced
NSCLC and
gastrointestinal
cancer,
breakdown NR
Stage NR
Handgrip strength
In Newton metre
for Biodex, and
pounds for Jamar
FFM
Jamar and Biodex
dynamometer
(n=74 completed)
DEXA, BIA (n=70
completed)
Cross
sectional
Nil Relationship
between DEXA
and BIA, and
Jamar and
Biodex
dynamometry
and their
precision in
patients with
advanced cancer
Biodex HGS mean
±SD: men 47.8
±13.6 vs women
32.7±9.3, p<0.05
Jamar HGS mean
±SD:
men 78.5±21.6 vs
women 49.7±13.5,
p<0.001;
%CV biodex 16.7%,
Jamar 6.3%
Wide limits of
agreement in
determining FFM,
DEXA vs BIA,
p=NS, but low %CV
for FFM DEXA
Continued
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Table 3 Continued
First author (year)
Patients Study
Comparison ResultN (M/F) Tumour, stage
Muscle function
and muscle mass
measurements
Method of
measurement Design Controls
(0.79) and BIA
(0.42)
Kilgour (2010)53 N=84, with
LC 16
(19%) of
cohort
(48/36)
Metastatic 57%,
locally advanced
43%, stage NR
HGS in kg, QS in
Newton metre
SMMI, ALM
Jamar (HGS) and
Biodex (QS)
DEXA
Cross
sectional
Nil Relationship of
fatigue to muscle
mass and
strength
HGS on fatigue,
95% CI −1.1 to
−0.15, p<0.05;
QS on fatigue, 95%
CI −0.2 to −0.01,
p<0.05;
Brief fatigue index
associated with
SMMI (95% CI −8.4
to −1.3) p<0.01, and
sarcopenia, p<0.01
Vigano (2009)52 N=172
(101/71)
NSCLC n=64,
Stage III and IV,
breakdown NR
Metastatic GI
cancer n=108
Handgrip force
and percentile
LBM, ALM
Jamar
dynamometer
DEXA (n=64)
Cross
sectional
Nil ACE gene
polymorphism
(insertion2-II,
insertion/
deletion-ID,
deletion2-DD) on
nutritional status
DD allele group
showed greater
handgrip force and
grip percentile than
II group, p<0.05; but
no difference in LBM
or ALM p=NS
Trend (p=0.07)
towards lower LBM
in ID compared to II
groups
Peddle-McIntyre
(2012)56
17 (7/10) NSCLC n=16
Stage I–II—11
Stage III—5
Limited stage
SCLC n=1
Chest press, Leg
press, functional
performance
measure (6MWD
—6-min walk
distance, GUAG,
chair stands and
arm curls in 30 s)
LBM, ALM
1RM in kg
DEXA
Longitudinal,
duration
10 weeks
Nil Resistance
exercise training
efficacy and
feasibility in lung
cancer survivors
Mean change from
baseline to end of
training in 95% CI
chest press 12.3 to
17.5, leg press 23.5
to 39.8, 6MWD 48
to 124, GUAG −0.4
to −1.2, chair stands
2.3 to 6.1, arm curls
2.1 to 5.1, all p<0.05
LBM and ALM no
change from
Continued
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Table 3 Continued
First author (year)
Patients Study
Comparison ResultN (M/F) Tumour, stage
Muscle function
and muscle mass
measurements
Method of
measurement Design Controls
baseline to post
training, all p=NS
Martinez-Hernandez
(2012)61
21 (19/2) Lung cancer
n=13, GI cancer
n=6, Other
cancer n=2
Stage according
to tumour group
NR
HGS and treadmill
6MWT
FFM
BIA Longitudinal n=8
healthy
volunteers
The role of IL-15
in patients with
cachectic cancer
HGS no difference
comparing cachectic
group to controls,
p=NS;
6MWT in cachectic
group 369±73 m vs
474±57 m, p<0.05
Op den Kamp
(2012)55
16 (15/1) NSCLC in all
Stage I–II—11
Stage IIIA—2
Stage IIIB—3
Intensity of
physical activity
FFMi
Triaxial
accelerometer
(Tracmor) in
counts/min
DEXA
Cross
sectional
n=10
healthy
volunteers
Skeletal muscle
ubiquitin
proteasome
system activity in
precachexia
High intensity
physical activity in
LC vs controls
p=0.049;
FFMi no significant
difference in
precachectic cancer
vs controls, p=NS
Op den Kamp
(2013)62
26 (17/9) NSCLC
Stage IIIB—10
Stage IV—16
QS)
FFMi, AMMi
DEXA Cross
sectional
n=10
healthy
volunteers
Expression of
signalling
molecules in
protein
metabolism in
lung cancer
cachexia
QS 31% lower in
cachectic group
compared to
controls, p<0.05
1RM, 1 Repetition-maximum; 6MWT, 6 min walk test; ALM, appendicular lean mass; AMA, Arm muscle area; AMMi, appendicular muscle mass index; BCM, body cell mass; BFMAMA, bone
free mid arm muscle area; BIA, bioelectrical impedance analysis; COPD, chronic obstructive pulmonary disease; DEXA, dual-energy X-ray absorptiometry; EPA, eicosapentaenoic acid;
F, female; FFM, fat-free mass; FFMi, FFM index; GI, gastrointestinal; GUAP, get-up-and-go; HGS, handgrip strength; IL-15, interleukin 15; LBM, lean body mass; LC, lung cancer; M, male;
MUAC, mid-upper arm circumference; NR, not recorded; NS, non-significant; NSCLC, non-small cell lung cancer; QS, quadriceps strength; RCT, randomised controlled trail; SCLC, small cell
lung cancer; SMMI, skeletal muscle mass index; MAC, mid arm circumference.
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proteolytic pathway may not be activated.55 80 Different
ACE-gene polymorphism allelic combinations52 and
leptin expression70 have not been shown to have signiﬁ-
cant effects on muscle mass. FFM is the major determin-
ant of energy metabolism in humans, represented by
resting energy expenditure (REE), and there exists a
linear relationship between REE and FFM in healthy
adults.81 In lung cancer cachexia, this relationship seems
to be distorted69 71 but results have been conﬂicting as
to whether REE contributes to the development of lung
cancer cachexia.67 68 72 73
The use of CT images for diagnosis of muscle mass
depletion alone showed a high prevalence of this phe-
nomenon in patients with NSCLC,25 regardless of body
mass index and even among the obese.1 CT images were
also used to chart progressive muscle loss over time, and
to create a prognostic model for survival based on
weight loss, muscle mass and muscle attenuation.65 66
The presence of muscle mass attenuation was associated
with poorer functional status and overall survival.
Nine interventional studies explored the effect of
either nutritional supplements or ATP infusions on
muscle mass and function. A randomised controlled
study with 518 participants, examining the effect of
eicosapentaenoic acid (found in ﬁsh oil) supplements,
revealed increased patient-rated physical functioning,
but no signiﬁcant change in FFM, at the end of the
study period.28 A similar, smaller study of eight partici-
pants concurred.75 By contrast, one study of ﬁsh oil sup-
plementation demonstrated a reduction in the rate of
loss of muscle mass; however, the number of studies was
small—40 patients in total. In addition, those considered
sarcopenic were found to have lower plasma fatty acids
than those without, in a study with 41 patients with
NSCLC.76 77 An interventional randomised controlled
study with 66 participants found that cysteine-rich
protein supplements increased FFM, as well as HGS,
compared with conventional protein supplements,54 and
a small case-control study with 10 patients found that
hyperaminoacidaemia stimulated a normal anabolic
protein response even in the presence of insulin resist-
ance, in patients with cancer cachexia.78 Two rando-
mised controlled studies investigating the effect of ATP
infusions on body composition gave conﬂicting reports,
one (N=58) ﬁnding that ATP slowed the rate of loss of
muscle mass50 while the other (N=100) did not.79 Only
the study by Fearon et al28 described power calculations
to detect a statistically signiﬁcant difference.
Degree of sarcopenia or loss of muscle mass and physical
functioning
There was very little direct evaluation of the relationship
between muscle mass and muscle function. However, the
studies that evaluated muscle mass alongside muscle
function show that there is limited correlation. Muscle
strength seemed to be affected, regardless of loss of
muscle mass. In patients with precachexia, exercise cap-
acity was signiﬁcantly reduced, despite maintenance of
muscle mass,55 and resistance exercise training increased
all parameters of muscle strength and physical perform-
ance, with no difference to muscle mass.56 In this review,
patients with cachexia showed reduced strength in terms
of walking distance61 and quadriceps strength62 com-
pared with controls.
DISCUSSION
Loss of muscle mass, as part of a weight-losing syndrome,
is a central feature of cancer cachexia. However, changes
in muscle mass, and/or performance, may predate clin-
ically overt cachexia, as part of ageing or secondary to
inﬂammation/disuse. This implies that consideration of
both muscle mass and function, rather than weight loss
alone, is clinically important. Understanding this rela-
tionship, and the factors associated with each, will
provide opportunities for focused intervention to
improve clinical outcomes.
The ﬁndings of our review highlight several import-
ant issues. While studies exploring molecular and meta-
bolic factors associated with loss of muscle mass have
contributed to a better understanding of the patho-
physiology of cancer cachexia, there remains consider-
able uncertainty in relation to mechanisms. Our review
in patients with lung cancer demonstrates inconsistency
of ﬁndings as to the factors implicated in the develop-
ment of cachexia, compared with other cancer sites. It
highlights the lack of clear therapeutic targets and
emphasises the need for concerted, appropriately-sized
exploration of predictive and prognostic factors in lung
cancer cachexia.
This uncertainty with regard to precise pathophysio-
logical mechanisms is reﬂected in the lack of consistent
effect of interventions aimed at slowing the rate of loss
Figure 1 Flowchart showing a breakdown of the results of
our search using the search terms used and the derivation of
articles for final analysis. FFM, fat-free mass.
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of muscle mass and improving muscle function in lung
cancer. Studies reviewed which refer to cachexia man-
agement support a multimodal approach, including tar-
geted exercise, nutritional counselling, social support
and pharmacological intervention.82 This review high-
lights inherent challenges of such an approach, with
nutritional interventions in particular failing to demon-
strate efﬁcacy,83 although the role of exercise is emer-
ging.56 84 It also suggests the need to represent patients
with NSCLC adequately within trials of new interven-
tions, such as myostatin antibody therapies, rather than
assuming a class effect across tumour sites.
Strikingly, our review has demonstrated that, to date,
there has not been due attention to the concept of sar-
copenia as a distinct, if overlapping syndrome, in a con-
dition affecting a largely elderly population. It also
highlights the difﬁculty in making comparisons between
studies, due to the heterogeneity of methods employed
in measuring muscle mass and different cut-off values
used for deﬁning sarcopenia. Current standardised
values were derived from a large elderly cohort and the
cut-off values were based on healthy young adult refer-
ence values. These values have been used to deﬁne sar-
copenia in cancer,13 85 including one in this review.53
The relevance of this deﬁnition to patients with cancer
is debatable, for a number of reasons. First, sarcopenia
manifests in patients with cancer of all ages and is not
isolated to the elderly alone. Second, the pathophysi-
ology of sarcopenia in patients with cancer may differ at
least in part to that of the non-cancer elderly popula-
tion.86 With this in mind, the more recent international
consensus document recommending a reference value
of absolute muscularity below the ﬁfth centile is to be
welcomed.13 Finally, the recognition of muscle strength
and performance as a deﬁning component of sarcope-
nia in the elderly patients needs consideration, within
the context of cancer cachexia.
The argument for the objective evaluation of physical
performance is pertinent, particularly as part of the
deﬁnitive assessment of sarcopenia alongside measure-
ments of muscle mass. Currently, physical ﬁtness for
treatment is determined largely by the PS score. This
score is imperfect as it is subjective, with reports of inter-
observer variability,87 and there is only a modest correl-
ation between PS and observed physical performance.88
Interclinician PS discordance has led to a lower percent-
age of PS 0 and 1 patients appearing to get chemother-
apy,89 and has led to a call for objective evaluation of
physical functioning.90 Some proposed methods include
tests of gait speed and muscle strength. It is postulated
that objective measures of muscle mass and strength
together may complement, or even outperform, PS as a
predictor of ﬁtness for systemic treatment, provided that
they can be readily performed in routine clinical
settings.
Our review has several limitations. The heterogeneity
of the studies included in this review made it difﬁcult to
account for individual risk of bias, not least because we
included a broad range of studies from large rando-
mised controlled trials to small observational studies.
This limitation also means that some articles included in
this review, while being relevant to sarcopenia, were
more broadly related to muscle mass outcomes in
cancer cachexia, rather than assessing sarcopenia dir-
ectly. Our search also was limited to studies published in
English, and although our review included some studies
with negative or inconclusive ﬁndings, there may indeed
exist some publication bias for which we are unable to
account.
The article by Temel et al,91 which demonstrated that
early palliative care involvement increased patient sur-
vival, as well as quality of life, has highlighted the
importance of supportive measures in a poor-prognosis
population receiving active oncological intervention. As
such, focusing research on the identiﬁcation and man-
agement of sarcopenia in patients with lung cancer may
prove to be a tolerable and cost-effective adjunct to the
current lung cancer care.
While development of a clearer deﬁnition of cancer
cachexia provides an additional component of a robust,
objective clinical framework for stratiﬁcation of patients
for focused interventions, the enhanced role of muscle
strength/performance as a deﬁning assessment of sarco-
penia requires attention. A standardised deﬁnition of
cancer-related sarcopenia which can be used clinically
and in the research setting will harmonise reporting,
allowing for direct comparison of results as well as
meta-analysis of data. In the era of stratiﬁed medicine,
this review identiﬁes opportunities to examine cellular
and genetic factors associated with sarcopenia in lung
cancer coherently and to link them with changes in
tumour phenotype which impact on morbidity and
survival.
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